ClinicalTrials.gg

Program

fenebrutinib

Also written as “GDC-0853”, “Fenebrutinib” and “Simvastatin and GDC-0853”.

Its studies are mostly in Multiple Sclerosis · Lupus Erythematosus, Systemic · Urticaria · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive, led by Hoffmann-La Roche.

Furthest: phase 3, since Sep 4, 202018 company-led studies, 6 open or runningNext primary completion: Jun 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche186 open or runningphase 3since Sep 4, 2020Nov 18, 2013Jun 8, 2027phase 2 · NCT07161258
  • Named in Hoffmann-La Roche’s own pipeline as RG7845 fenebrutinib, phase 4, as of Oct 22, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 18, 2013.

  1. Sep 14, 2016Phase 2 study in Lupus Erythematosus, SystemicNCT02908100 · 260 enrolled · United States, Argentina, Brazil and more
  2. Nov 29, 2016Phase 2 study in Arthritis, RheumatoidNCT02983227 · 496 enrolled · United States, Argentina, Brazil and more
  3. Apr 28, 2017Phase 2 study in UrticariaNCT03137069 · 134 enrolled · United States, Canada, Germany
  4. May 4, 2017Phase 1 study in Healthy ParticipantsNCT03174041 · 63 enrolled · United States
  5. Jun 14, 2017Phase 1 study in Healthy VolunteerNCT03188783 · 32 enrolled · United States
  6. Sep 19, 2017Phase 1 study in Healthy VolunteersNCT03290703 · 63 enrolled · United Kingdom
  7. Jan 15, 2018Phase 2 study in Lupus Erythematosus, SystemicNCT03407482 · 160 enrolled · United States, Argentina, Brazil and more
  8. Jul 13, 2018Phase 1 study in Healthy ParticipantsNCT03596632 · 8 enrolled · United States
  9. Oct 1, 2018Phase 2 study in UrticariaNCT03693625 · 31 enrolled · United States
  10. Sep 4, 2020Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT04544449 · 985 enrolled · United States, Argentina, Australia and more
  11. Oct 8, 20202 phase 3 studies in Relapsing Multiple SclerosisNCT04586023, NCT04586010
  12. Oct 29, 2021Phase 2 study in Relapsing Multiple SclerosisNCT05119569 · 109 enrolled · United States, Bosnia and Herzegovina, Croatia and more
  13. Aug 20, 2025Phase 2 study in Relapsing Multiple SclerosisNCT07161258 · 12 planned · Argentina, Brazil, Mexico and more
  14. Nov 10, 2026Phase 3 study in Multiple SclerosisNCT07937852 · 1,800 planned

Ahead

  1. Jun 8, 2027Primary completion: phase 2 study in Relapsing Multiple SclerosisNCT07161258
  2. Nov 30, 2029Primary completion: phase 3 study in Multiple SclerosisNCT07937852

TargetBeta

“An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, fenebrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-m…”NCIt, read by Claude
“An orally available inhibitor of Bruton's tyrosine kinase (BTK) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07937852Multiple Sclerosis3Not yet recruitingNov 30, 20291,800
NCT07161258Relapsing Multiple Sclerosis · Argentina, Brazil, Mexico and more2RecruitingJun 8, 202712
NCT05119569Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Croatia and more2Active, not recruitingMar 29, 2023109
NCT04586023Relapsing Multiple Sclerosis · United States, Austria, Brazil and more3Active, not recruitingSep 5, 2025751
NCT04586010Relapsing Multiple Sclerosis · United States, Argentina, China and more3Active, not recruitingJan 27, 2026746
NCT04544449Multiple Sclerosis, Chronic Progressive · United States, Argentina, Australia and more3Active, not recruitingSep 17, 2025985
NCT03693625Urticaria · United States2TerminatedOct 23, 201931
NCT03596632Healthy Participants · United States1CompletedAug 23, 20188
NCT03407482Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2TerminatedNov 20, 2019160
NCT03290703Healthy Volunteers · United Kingdom1CompletedOct 25, 201863
NCT03188783Healthy Volunteer · United States1CompletedAug 9, 201732
NCT03174041Healthy Participants · United States1CompletedJun 23, 201763
NCT03137069Urticaria · United States, Canada, Germany2CompletedSep 27, 2019134
NCT02983227Arthritis, Rheumatoid · United States, Argentina, Brazil and more2CompletedJul 17, 2019496
NCT02908100Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more2CompletedMay 28, 2019260
NCT02833350Arthritis, Rheumatoid · United States, Argentina, Brazil and more2CompletedJul 2, 2018578
NCT02699710Healthy Volunteer · United Kingdom1CompletedMay 26, 201650
NCT01991184Leukemia, Lymphoid · United States, Australia1CompletedMar 8, 202224

How it is read

Names in the registry

  • “GDC-0853”, 12 entries
  • “Fenebrutinib”, 7 entries
  • “Simvastatin and GDC-0853”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.